Disc Medicine, Inc. (NASDAQ:IRON) CFO Sells $171,162.88 in Stock

Disc Medicine, Inc. (NASDAQ:IRON) CFO Jean M. Franchi sold 3,136 shares of the firm’s stock in a transaction dated Tuesday, February 18th. The stock was sold at an average price of $54.58, for a total transaction of $171,162.88. Following the sale, the chief financial officer now owns 69,530 shares of the company’s stock, valued at approximately $3,794,947.40. The trade was a 4.32 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink.

Disc Medicine Trading Down 0.2 %

Shares of IRON stock opened at $54.35 on Friday. Disc Medicine, Inc. has a 12 month low of $25.60 and a 12 month high of $77.60. The firm has a fifty day moving average price of $59.26 and a 200 day moving average price of $55.02.

Wall Street Analyst Weigh In

A number of analysts recently issued reports on the company. Wedbush reissued an “outperform” rating and set a $90.00 price objective (up from $83.00) on shares of Disc Medicine in a research report on Tuesday, January 21st. Raymond James raised shares of Disc Medicine from an “outperform” rating to a “strong-buy” rating and boosted their price target for the company from $66.00 to $110.00 in a research note on Monday, November 4th. HC Wainwright reaffirmed a “buy” rating and set a $118.00 price objective on shares of Disc Medicine in a research report on Tuesday, January 21st. Scotiabank boosted their target price on Disc Medicine from $70.00 to $73.00 and gave the company a “sector outperform” rating in a research report on Wednesday, January 22nd. Finally, Morgan Stanley upgraded Disc Medicine from an “equal weight” rating to an “overweight” rating and set a $85.00 price target for the company in a research report on Tuesday, November 5th. Nine analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Buy” and an average price target of $88.90.

Hedge Funds Weigh In On Disc Medicine

A number of institutional investors and hedge funds have recently added to or reduced their stakes in IRON. Geode Capital Management LLC boosted its holdings in shares of Disc Medicine by 17.6% in the 3rd quarter. Geode Capital Management LLC now owns 474,719 shares of the company’s stock valued at $23,333,000 after buying an additional 70,983 shares in the last quarter. State Street Corp boosted its stake in Disc Medicine by 39.7% in the third quarter. State Street Corp now owns 827,910 shares of the company’s stock valued at $40,683,000 after acquiring an additional 235,115 shares in the last quarter. Verition Fund Management LLC purchased a new position in shares of Disc Medicine during the third quarter worth about $589,000. Mirae Asset Global Investments Co. Ltd. increased its position in shares of Disc Medicine by 45.7% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,075 shares of the company’s stock worth $54,000 after purchasing an additional 337 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. lifted its holdings in shares of Disc Medicine by 13.7% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 160,554 shares of the company’s stock valued at $7,890,000 after purchasing an additional 19,401 shares during the last quarter. 83.70% of the stock is owned by institutional investors and hedge funds.

About Disc Medicine

Disc Medicine, Inc, together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases in the United States. The company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, primarily heme biosynthesis and iron homeostasis.